Alamar Biosciences, Inc. (NASDAQ: ALMR) launched the NULISAseq Immune 340 Panel on July 28, 2026, introducing its broadest multiplexed immune profiling solution for translational research and drug development. The new panel allows researchers to measure approximately 340 immune-related proteins simultaneously from a single sample, addressing detection gaps in low-concentration biomarkers that signal disease before symptoms appear. This expansion builds on the company’s existing NULISAseq Inflammation Panel 250, aiming to accelerate biomarker discovery and strengthen therapy development across cancer, cardiovascular, metabolic, autoimmune diseases, and aging research.

The launch addresses significant challenges in detecting immune mediators such as cytokines, chemokines, and cell death pathway markers, which often circulate at fg/mL to sub-pg/mL concentrations. These levels are typically below the detection floor of conventional immunoassays, particularly in inflammaging—the chronic, low-grade inflammation associated with aging that drives risk for cardiovascular, metabolic, neurodegenerative, and cancer conditions. By capturing these previously invisible signals, Alamar seeks to provide deeper insights into the immune proteome.

Key Features of NULISAseq Immune 340

Dr. Yuling Luo, founder, chief executive officer and chair of Alamar Biosciences, stated that the immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach. He noted that the NULISAseq Immune 340 provides an unprecedented view of immune activity, which he believes will accelerate biomarker discovery and advance the company’s mission of detecting disease earlier.

Industry Validation

Bailin Zhang, PhD, head of exploratory biomarkers in the Translational Medicine Unit at Sanofi, highlighted the panel’s distinctive combination of breadth and sensitivity. Zhang explained that many proteins relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. He added that accessing these markers alongside canonical ones in one multiplexed run opens new possibilities for biomarker discovery and patient stratification in drug development.

What the Numbers Show

The expansion from the 250-protein Inflammation Panel to the 340-protein Immune Panel represents a 36% increase in measurable targets. This growth reflects Alamar’s strategy to capture broader pathway crosstalk and feedback loops rather than isolated protein signals. The ability to detect sub-pg/mL concentrations differentiates the offering from conventional immunoassays, potentially reducing the need for multiple testing platforms in early-stage research. This integration could streamline workflows for pharmaceutical partners seeking comprehensive immune landscape profiles from limited sample volumes.

Alamar Biosciences, Inc. will release its financial results for the second quarter of 2026 after market close on Monday, August 10, 2026. The announcement will provide insights into the company's performance for the quarter ending June 30, 2026. Following the release, company management will host a conference call to discuss the results.

The conference call is scheduled to begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live audio webcast through the "Investors" section of the Alamar Biosciences website. The webcast will be archived and available for replay after the event for those unable to attend the live session.

Key Details

Alamar Biosciences is a commercial-stage proteomics company focused on advancing protein detection and analysis. The company leverages its proprietary NULISA™ technology and the ARGO™ HT System to enable high-sensitivity biomarker detection. This approach aims to support early disease detection and research across various disease states.

Investors and interested parties can visit the company's website for more information. The archived webcast will provide a convenient option for reviewing the discussion at a later time.